A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

摘要: BACKGROUND Obesity is a chronic disease with serious health consequences, but weight loss difficult to maintain through lifestyle intervention alone. Liraglutide, glucagonlike peptide-1 analogue, has been shown have potential benefit for management at once-daily dose of 3.0 mg, injected subcutaneously. METHODS We conducted 56-week, double-blind trial involving 3731 patients who did not type 2 diabetes and had body-mass index (BMI; the in kilograms divided by square height meters) least 30 or BMI 27 if they treated untreated dyslipidemia hypertension. randomly assigned 2:1 ratio receive subcutaneous injections liraglutide mg (2487 patients) placebo (1244 patients); both groups received counseling on modification. The coprimary end points were change body proportions losing 5% more than 10% their initial weight. RESULTS At baseline, mean (±SD) age was 45.1±12.0 years, 106.2±21.4 kg, 38.3±6.4; total 78.5% women 61.2% prediabetes. week 56, group lost 8.4±7.3 kg weight, those 2.8±6.5 (a difference −5.6 kg; 95% confi dence interval, −6.0 −5.1; P<0.001, last-observation-carried-forward impu tation). A 63.2% as compared 27.1% (P<0.001), 33.1% 10.6%, respectively, (P<0.001). most frequently reported adverse events mild moderate nausea diarrhea. Serious occurred 6.2% 5.0% group. CONCLUSIONS In this study, liraglutide, an adjunct diet exercise, associated reduced improved metabolic control. (Funded Novo Nordisk; SCALE Prediabetes NN8022-1839 ClinicalTrials.gov number, NCT01272219.)